OTTAWA, Sept. 27 /CNW/ - Liponex Inc. (TSX:LPX), a biopharmaceutical
company specializing in developing advanced products related to High Density
Lipoprotein (HDL), often called "good cholesterol," announced today that the
company will present a CRD5 development update at the 16th International
Symposium for Drugs Affecting Lipid Metabolism (DALM). Dr. Daniel Sparks,
founder and Chief Scientific Officer of Liponex, will give the presentation
entitled, "Clinical Development of a Novel HDL Therapeutic" on October 5, 2007
in New York City.
